

Jai Radhakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8692520/publications.pdf>

Version: 2024-02-01

197
papers

13,757
citations

24978

57
h-index

23472

111
g-index

221
all docs

221
docs citations

221
times ranked

14014
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathologic Classification of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2010, 21, 556-563.	3.0	1,191
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	2.6	782
3	Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature, 2012, 482, 98-102.	13.7	560
4	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	6.3	526
5	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 142-151.	13.9	456
6	Acute Phosphate Nephropathy following Oral Sodium Phosphate Bowel Purgative: An Underrecognized Cause of Chronic Renal Failure. Journal of the American Society of Nephrology: JASN, 2005, 16, 3389-3396.	3.0	358
7	Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney International, 2003, 64, 281-289.	2.6	333
8	The KDIGO practice guideline on glomerulonephritis: reading between the (guide)linesâ€™ application to the individual patient. Kidney International, 2012, 82, 840-856.	2.6	332
9	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	2.6	325
10	Lithium Nephrotoxicity. Journal of the American Society of Nephrology: JASN, 2000, 11, 1439-1448.	3.0	306
11	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 748-756.	2.2	295
12	Presentation and Outcomes of Patients with ESKD and COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1409-1415.	3.0	270
13	Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney International, 2010, 78, 1171-1177.	2.6	257
14	Postmortem Kidney Pathology Findings in Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 2158-2167.	3.0	241
15	Donor-Specific Antibodies Adversely Affect Kidney Allograft Outcomes. Journal of the American Society of Nephrology: JASN, 2012, 23, 2061-2071.	3.0	234
16	The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1718-1724.	2.2	227
17	Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International, 2017, 92, 37-46.	2.6	220
18	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1278-1287.	3.0	210

#	ARTICLE	IF	CITATIONS
19	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
20	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	8.3	197
21	Bacterial infection-related glomerulonephritis in adults. <i>Kidney International</i> , 2013, 83, 792-803.	2.6	196
22	Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2139-2145.	0.4	195
23	Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. <i>Kidney International Reports</i> , 2020, 5, 1149-1160.	0.4	184
24	Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1676-1683.	2.2	180
25	Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2039-2046.	0.4	172
26	Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. <i>Kidney International</i> , 2010, 77, 152-160.	2.6	167
27	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. <i>Kidney International</i> , 2017, 91, 787-789.	2.6	161
28	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 100.	2.0	154
29	Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2362-2370.	1.1	145
30	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135
31	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2745-2754.	3.0	128
32	Renal Biopsy in the Very Elderly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1073-1082.	2.2	124
33	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. <i>Kidney International</i> , 2018, 93, 977-985.	2.6	123
34	The Treatment of Minimal Change Disease in Adults. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 702-711.	3.0	116
35	Glomerular diseases seen with cancer and chemotherapy: a narrative review. <i>Kidney International</i> , 2013, 84, 34-44.	2.6	106
36	Use of mycophenolate mofetil in resistant membranous nephropathy. <i>American Journal of Kidney Diseases</i> , 2000, 36, 250-256.	2.1	105

#	ARTICLE	IF	CITATIONS
37	The pathophysiology of edema formation in the nephrotic syndrome. <i>Kidney International</i> , 2012, 82, 635-642.	2.6	102
38	Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study. <i>Diabetes Care</i> , 2003, 26, 1402-1407.	4.3	99
39	Awareness of kidney disease in the US population: Findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. <i>American Journal of Kidney Diseases</i> , 2004, 44, 185-197.	2.1	99
40	Mycophenolate Mofetil for the Treatment of Interstitial Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 718-722.	2.2	95
41	Rationale and design of the Kidney Precision Medicine Project. <i>Kidney International</i> , 2021, 99, 498-510.	2.6	94
42	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. <i>Kidney International Reports</i> , 2017, 2, 800-810.	0.4	89
43	Treatment of Idiopathic FSGS with Adrenocorticotrophic Hormone Gel. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2072-2081.	2.2	86
44	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. <i>Kidney International</i> , 2014, 86, 246-250.	2.6	84
45	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH) gel. <i>Drug Design, Development and Therapy</i> , 2011, 5, 147.	2.0	83
46	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	1.4	83
47	The relevance of congestion in the cardio-renal syndrome. <i>Kidney International</i> , 2013, 83, 384-391.	2.6	80
48	Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates. <i>JAMA Network Open</i> , 2019, 2, e1910312.	2.8	78
49	ANCA-associated glomerulonephritis in the very elderly. <i>Kidney International</i> , 2011, 79, 757-764.	2.6	77
50	Drug-Induced Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1300-1310.	2.2	75
51	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. <i>Transplantation</i> , 2007, 83, 539-545.	0.5	73
52	Race/Ethnicity, Poverty Status, and Renal Transplant Outcomes. <i>Transplantation</i> , 2005, 80, 917-924.	0.5	71
53	Angiotensin converting enzyme inhibition in chronic allograft nephropathy. <i>Transplantation</i> , 2002, 73, 783-788.	0.5	70
54	Gastrointestinal disorders and renal failure: exploring the connection. <i>Nature Reviews Nephrology</i> , 2010, 6, 480-492.	4.1	68

#	ARTICLE	IF	CITATIONS
55	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	2.1	68
56	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	2.2	66
57	Genomic Mismatch at <i>LIMS1</i> Locus and Kidney Allograft Rejection. <i>New England Journal of Medicine</i> , 2019, 380, 1918-1928.	13.9	63
58	Use of Mycophenolate Mofetil in Autoimmune and Renal Diseases. <i>Transplantation</i> , 2005, 80, S265-S271.	0.5	62
59	Advances in the Treatment of Lupus Nephritis. <i>Annual Review of Medicine</i> , 2001, 52, 63-78.	5.0	57
60	Procurement Biopsies in the Evaluation of Deceased Donor Kidneys. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1876-1885.	2.2	57
61	Renal Transplantation in Anticardiolipin Antibody-Positive Lupus Erythematosus Patients. <i>American Journal of Kidney Diseases</i> , 1994, 23, 286-289.	2.1	56
62	De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 203-209.	0.4	50
63	Renal-limited 'lupus-like' nephritis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2337-2342.	0.4	50
64	IgA Nephropathy with Minimal Change Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1033-1039.	2.2	49
65	Rituximab treatment for fibrillary glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1925-1931.	0.4	47
66	High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. <i>PLoS ONE</i> , 2020, 15, e0244131.	1.1	46
67	Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. <i>Seminars in Nephrology</i> , 2003, 23, 406-411.	0.6	42
68	Early experience with COVID-19 in kidney transplantation. <i>Kidney International</i> , 2020, 97, 1074-1075.	2.6	41
69	The Role of Kidney Biopsy in Heart Transplant Candidates With Kidney Disease. <i>Transplantation</i> , 2010, 89, 887-893.	0.5	40
70	Antiphospholipid antibody syndrome and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 175-181.	1.0	39
71	Under-documentation of chronic kidney disease in the electronic health record in outpatients. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2010, 17, 588-594.	2.2	39
72	Drug-Induced Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1287-1290.	2.2	39

#	ARTICLE	IF	CITATIONS
73	Association between Reperfusion Renal Allograft Biopsy Findings and Transplant Outcomes. Journal of the American Society of Nephrology: JASN, 2017, 28, 3109-3117.	3.0	39
74	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.4	39
75	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.4	39
76	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	2.6	38
77	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	2.5	37
78	Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney International, 2010, 78, 337-342.	2.6	36
79	Glomerular Diseases Associated With Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Advances in Chronic Kidney Disease, 2014, 21, 48-55.	0.6	36
80	Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney International, 2018, 94, 1189-1198.	2.6	36
81	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. Journal of the American Society of Hypertension, 2012, 6, 338-345.	2.3	35
82	CYCLOSPORINE TREATMENT OF GLOMERULAR DISEASES. Annual Review of Medicine, 1999, 50, 1-15.	5.0	31
83	Idiopathic Membranous Nephropathy: Clinical and Histologic Prognostic Features and Treatment Patterns over Time at a Tertiary Referral Center. American Journal of Nephrology, 2012, 36, 78-89.	1.4	31
84	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovascular Interventions, 2022, 15, 753-766.	1.1	31
85	Thrombotic microangiopathies. Critical Care Clinics, 2002, 18, 309-320.	1.0	30
86	Importance of stratifying acute kidney injury in cardiogenic shock resuscitated with mechanical circulatory support therapy. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 856-864.e4.	0.4	30
87	The Epidemiology of Peritonitis in Acute Peritoneal Dialysis: A Comparison Between Open- and Closed-Drainage Systems. American Journal of Kidney Diseases, 1993, 21, 300-309.	2.1	29
88	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 651-664.	2.2	28
89	Towards the Incidence of Acute Phosphate Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 3020-3022.	3.0	26
90	Trimethoprim-Associated Hyponatremia. American Journal of Kidney Diseases, 2013, 62, 1188-1192.	2.1	26

#	ARTICLE	IF	CITATIONS
91	Is Newer Safer? Adverse Events Associated with First-Line Therapies for ANCA-Associated Vasculitis and Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1657-1667.	2.2	26
92	Lupus Nephritis: Treatment of Resistant Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 154-161.	2.2	24
93	One year follow up analysis of the phase 1a/b study of chimeric fibrin-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 115-116.	1.4	24
94	How COVID-19 Has Changed the Management of Glomerular Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 876-879.	2.2	23
95	Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device. <i>Circulation: Heart Failure</i> , 2020, 13, e006326.	1.6	22
96	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). <i>Discovery Medicine</i> , 2011, 12, 91-6.	0.5	22
97	The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. <i>Frontiers in Pediatrics</i> , 2015, 3, 78.	0.9	21
98	Monoclonal IgG1 ^κ Anti-“Glomerular Basement Membrane Disease: A Case Report. <i>American Journal of Kidney Diseases</i> , 2015, 65, 322-326.	2.1	21
99	Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 374-383.	2.1	21
100	Standardized Outcomes in Nephrology-“Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	2.6	20
101	Radiographic Periodontal Bone Loss in Chronic Kidney Disease. <i>Journal of Periodontology</i> , 2012, 83, 602-611.	1.7	19
102	Racial and socioeconomic factors in glomerular disease. <i>Seminars in Nephrology</i> , 2001, 21, 403-410.	0.6	19
103	Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. <i>Clinical Nephrology</i> , 2012, 77, 366-375.	0.4	18
104	The Treatment of Idiopathic Focal Segmental Glomerulosclerosis in Adults. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 434-441.	0.6	18
105	Results of Phase I Study of Chimeric Fibrin-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. <i>Blood</i> , 2015, 126, 188-188.	0.6	18
106	Transjugular Intrahepatic Portosystemic Shunts in Hemodialysis-dependent Patients and Patients with Advanced Renal Insufficiency: Safety, Caution, and Encephalopathy. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 516-520.	0.2	17
107	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. <i>Kidney International Reports</i> , 2020, 5, 1679-1689.	0.4	17
108	The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1066-1072.	2.2	17

#	ARTICLE	IF	CITATIONS
109	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. <i>Kidney International</i> , 2021, 100, 440-446.	2.6	17
110	Concurrent Anti-“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2021, 78, 219-225.e1.	2.1	16
111	Rituximab Treatment of Dysproteinemias Affecting the Kidney: A Review of Three Cases. <i>American Journal of Kidney Diseases</i> , 2007, 50, 641-644.	2.1	15
112	Renal Transplantation in Familial Dysautonomia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1676-1680.	2.2	15
113	The changing pattern of glomerular disease in HIV and Hepatitis C co-infected patients in the era of HAART. <i>Clinical Nephrology</i> , 2013, 79, 285-291.	0.4	15
114	A rare infectious cause of renal allograft dysfunction. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1103-1107.	2.1	14
115	Worth a Second Look. <i>American Journal of Medicine</i> , 2009, 122, 24-26.	0.6	14
116	Live Donor Renal Anatomic Asymmetry and Posttransplant Renal Function. <i>Transplantation</i> , 2015, 99, e66-e74.	0.5	14
117	A Newly Recognized Endemic Region of CKD of Undetermined Etiology (CKDu) in South India-“Tondaimandalam Nephropathy”. <i>Kidney International Reports</i> , 2020, 5, 2066-2073.	0.4	14
118	An overlapping etiology of rapidly progressive glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2004, 43, 388-393.	2.1	13
119	A 56-year-old woman with sarcoidosis and acute renal failure. <i>Kidney International</i> , 2008, 74, 817-821.	2.6	13
120	Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?. <i>Kidney International</i> , 2012, 82, 1256-1260.	2.6	13
121	Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. <i>Heart Failure Reviews</i> , 2015, 20, 283-290.	1.7	13
122	Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort. <i>Clinical Nephrology</i> , 2015, 84 (2015), 145-155.	0.4	13
123	Cyclosporin treatment of glomerular diseases. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1053-1063.	1.9	12
124	Cryofibrinogen-Associated Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 302-308.	2.1	12
125	Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 643-643.	0.6	12
126	Case 5-2010. <i>New England Journal of Medicine</i> , 2010, 362, 636-646.	13.9	11

#	ARTICLE	IF	CITATIONS
127	Proteinuria as a surrogate marker for renal outcome: are we there yet?. <i>Kidney International</i> , 2015, 88, 1228-1230.	2.6	11
128	Persistent Hepatitis C Virus-Associated Cryoglobulinemic Glomerulonephritis in Patients Successfully Treated With Direct-Acting Antiviral Therapy. <i>Kidney International Reports</i> , 2018, 3, 985-990.	0.4	11
129	Capillary leak syndrome: a cytokine and catecholamine storm?. <i>Kidney International</i> , 2019, 95, 1009-1011.	2.6	10
130	Fludarabine treatment of cryoglobulinemic glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2002, 40, 644-648.	2.1	9
131	Pharmacological Effects of Ex Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation. <i>Stem Cells Translational Medicine</i> , 2021, 10, 1588-1601.	1.6	9
132	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. <i>Glomerular Diseases</i> , 2022, 2, 42-53.	0.2	9
133	Do meta-analyses in nephrology change the way we treat patients?. <i>Kidney International</i> , 2010, 78, 1080-1087.	2.6	8
134	Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 527-534.	0.4	8
135	In-Hospital Survival and Neurological Recovery Among Patients Requiring Renal Replacement Therapy in Post-Cardiac Arrest Period. <i>Kidney International Reports</i> , 2019, 4, 674-678.	0.4	8
136	Venous Thromboembolism and Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 3-4.	2.2	7
137	Dashboards to Facilitate Nephrology Disaster Planning in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1298-1302.	0.4	7
138	Optimizing Kidney Replacement Therapy During the COVID-19 Pandemic Across a Complex Healthcare System. <i>Frontiers in Medicine</i> , 2020, 7, 604182.	1.2	7
139	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	2.6	7
140	Evaluation of a computer program for teaching laboratory diagnosis of acid-base disorders. <i>Journal of Biomedical Informatics</i> , 1992, 25, 562-568.	0.7	6
141	Nephrological and obstetric complications of the antiphospholipid syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 819-829.	1.9	6
142	A pharmacist-physician collaborative care model in chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2021, 23, 2026-2029.	1.0	6
143	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. <i>Kidney Medicine</i> , 2022, 4, 100457.	1.0	6
144	Temporal Changes in Post-Infectious Glomerulonephritis in Japan (1976-2009). <i>PLoS ONE</i> , 2016, 11, e0157356.	1.1	5

#	ARTICLE	IF	CITATIONS
145	Anticomplement therapies in “secondary thrombotic microangiopathies” ready for prime time?. <i>Kidney International</i> , 2019, 96, 833-835.	2.6	5
146	Ultra-low-contrast angiography in patients with advanced chronic kidney disease and previous coronary artery bypass surgery. <i>Coronary Artery Disease</i> , 2019, 30, 346-351.	0.3	5
147	Patient perspectives and involvement in precision medicine research. <i>Kidney International</i> , 2021, 99, 511-514.	2.6	5
148	Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. <i>ASAIO Journal</i> , 2021, 67, 1087-1096.	0.9	5
149	Citius, altius, fortius . . . faster, higher, stronger. <i>Kidney International</i> , 2019, 95, 476-478.	2.6	4
150	Pathogenesis of SLE Nephritis in the Era of Precision Medicine. <i>Current Rheumatology Reviews</i> , 2018, 14, 140-144.	0.4	4
151	Treating lupus in the kidney: where are we now, and where are we going?. <i>Discovery Medicine</i> , 2011, 12, 341-9.	0.5	4
152	A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.	2.2	4
153	The Case of Renal failure after percutaneous closure of a perivalvular leak. <i>Kidney International</i> , 2008, 74, 539-540.	2.6	3
154	Risk factors for chronic kidney disease following acute kidney injury in pediatric allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1665-1673.	1.3	3
155	Hemoglobinuric acute kidney injury from aortic root graft malfunction. <i>Clinical Nephrology</i> , 2014, 82, 221-4.	0.4	3
156	A challenge to the kidney community by a man-made crisis. <i>Kidney International</i> , 2022, 101, 854-855.	2.6	3
157	The burden of prescription coverage of kidney failure patients in the United States: is Medicare Part D the answer?. <i>Kidney International</i> , 2006, 69, 1099-1100.	2.6	2
158	The Authors Reply.. <i>Kidney International</i> , 2014, 85, 214.	2.6	2
159	Native Valve Emphysematous Endocarditis Caused by <i>Fingoldia magna</i> in a Novel Pathogenic Role. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 57-59.	0.1	2
160	TCT-32 Clinical Outcomes of Imaging- and Physiology-Guided PCI Without Contrast Administration in Advanced Renal Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, B32.	1.2	2
161	Reversal of Donor Hepatitis C Virus-Related Mesangial Proliferative GN in a Kidney Transplant Recipient. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2246-2249.	3.0	2
162	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.4	2

#	ARTICLE	IF	CITATIONS
163	The Case Euglycemic ketoacidosis in a patient on continuous renal replacement therapy. <i>Kidney International</i> , 2021, 99, 1507-1508.	2.6	2
164	A focus group study of self-management in patients with glomerular disease.. <i>Kidney International Reports</i> , 2021, 7, 56-67.	0.4	2
165	Strategies for Renal Protection in Cardiovascular Interventions. <i>Korean Circulation Journal</i> , 2022, 52, 485.	0.7	2
166	A case of nephrocalcinosis. <i>Kidney International</i> , 2009, 75, 856-859.	2.6	1
167	Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 136-137.	2.2	1
168	KI Reports and World Kidney Day. <i>Kidney International Reports</i> , 2017, 2, 125-126.	0.4	1
169	Kidney International Reports : The First Year. <i>Kidney International Reports</i> , 2017, 2, 503.	0.4	1
170	KI Reports in 2019: Further Expanding Access to Research in Nephrology. <i>Kidney International Reports</i> , 2019, 4, 1-2.	0.4	1
171	Kidney International Reports: Three Years of Publication. <i>Kidney International Reports</i> , 2020, 5, 117.	0.4	1
172	Kidney International and the COVID-19 infection. <i>Kidney International</i> , 2020, 97, 823.	2.6	1
173	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2021, 99, 2-4.	2.6	1
174	Reflections and Next Stages for Kidney International Reports. <i>Kidney International Reports</i> , 2021, 6, 1-2.	0.4	1
175	Looking back and moving forward. <i>Kidney International</i> , 2021, 99, 787-790.	2.6	1
176	Successful Use of Arteriovenous Graft for Hemodialysis Access After Left Ventricular Assist Device Placement. <i>Kidney Medicine</i> , 2021, 3, 1091-1094.	1.0	1
177	Impact of bone marrow minimal residual disease status on quality of organ response in systemic amyloidosis. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
178	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. <i>Kidney International Reports</i> , 2022, 7, 2076-2080.	0.4	1
179	Polycystic liver disease treated with therapeutic excision. <i>Kidney International</i> , 2009, 76, 803.	2.6	0
180	Back-bench split of a deceased-donor horseshoe kidney for two transplant recipients. <i>Kidney International</i> , 2009, 76, 1012.	2.6	0

#	ARTICLE	IF	CITATIONS
181	The Authors Reply:. Kidney International, 2013, 83, 969.	2.6	0
182	The Evolution of Treating Glomerular Diseases: Letting Science Lead the Way. Advances in Chronic Kidney Disease, 2014, 21, 119-120.	0.6	0
183	The Author Replies:. Kidney International, 2015, 87, 664.	2.6	0
184	Good news and best wishes for 2016 to the global nephrology community from Kidney International. Kidney International, 2016, 89, 2.	2.6	0
185	The Launch of Kidney International Reports. Kidney International Reports, 2016, 1, 1-2.	0.4	0
186	A 31-Year-Old Man With a Ring-Enhancing Brain Lesion. Journal of Neuro-Ophthalmology, 2017, 37, 172-175.	0.4	0
187	Kidney International Reports: Two Years of Publication. Kidney International Reports, 2018, 3, 509.	0.4	0
188	Intensive BP control and incident kidney disease: what can we learn fromÂurinaryÂbiomarkers?. Kidney International, 2019, 95, 1007-1009.	2.6	0
189	The Case A hidden deposit. Kidney International, 2020, 97, 815-816.	2.6	0
190	Treatment of glomerular diseases: pioneering clinical trials. Kidney International, 2020, 97, 433-436.	2.6	0
191	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	0.9	0
192	Five Years (and Counting) of Expanding Access to Kidney Disease Research. Kidney International Reports, 2021, 6, 1487-1488.	0.4	0
193	Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience. Blood, 2019, 134, 5565-5565.	0.6	0
194	ANCA Vasculitis Treatment in the Dialysis Patient. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1617-1619.	2.2	0
195	Low glomerular filtration rate in apparently healthy young individuals is an important factor preventing kidney transplantation from living kidney donors â€“ A single-center observational study from India. Indian Journal of Transplantation, 2021, 15, 325.	0.0	0
196	Six Years of KI Reports: Milestones Behind and Ahead. Kidney International Reports, 2022, 7, 1-2.	0.4	0
197	Diagnosis and Treatment of Patients With FSGS/SRNS: A Delphi Survey. Kidney International Reports, 2022, , .	0.4	0